{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:23:22Z","timestamp":1794435802409,"version":"4.9.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Pituitary tumors are a heterogeneous group of neoplasms exhibiting a wide range of clinical and histological features. There are currently no comprehensive clinically validated prognostic tools to guide management of all tumor types before and after surgery. Recently, the PANOMEN 3 classification, incorporating risk factors for disease severity, was proposed as a potential grading system to assess prognosis. We aimed to evaluate the clinical utility and application of the new PANOMEN 3 classification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study of 215 cases of pituitary tumors surgically resected at Westmead Hospital between 2011 and 2018. All tumors were histologically examined according to the 2022 WHO Classification of pituitary tumors. Preoperative and postoperative PANOMEN 3 grades were assigned, and recurrence analyses performed. Results were compared to the French clinicopathological classification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared to PANOMEN 3 grade 0, risk of recurrence was highest for grade 3 (HR 10.99; 95% CI 1.14-106.11, P = .038), followed by grade 2 (HR 7.85; 95% CI 1.06-58.31, P = .044), but not significantly different for grade 1. Proportions of tumors needing further intervention was greater with higher PANOMEN 3 grades; interventions occurred earlier in high grade tumors. The French classification remained a significant predictor of recurrence when adjusted for PANOMEN 3 (P &amp;lt; .001), but PANOMEN 3 was not a strong predictor when adjusted for French classification (P = .374).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the postoperative setting, PANOMEN 3 classification is useful in prediction of recurrence and need for further therapy. However, it was a weaker tool for predicting recurrence than the French classification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvaf122","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T07:50:27Z","timestamp":1750924227000},"page":"56-64","source":"Crossref","is-referenced-by-count":10,"title":["Assessing the clinical application of the PANOMEN 3 classification in a large cohort of pituitary tumors"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9314-9733","authenticated-orcid":false,"given":"Prishila","family":"Fookeerah","sequence":"first","affiliation":[{"name":"Department of Diabetes and Endocrinology, Westmead Hospital , Sydney, NSW 2145 ,","place":["Australia"]},{"name":"School of Medicine, Western Sydney University , Sydney, NSW 2560 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winny","family":"Varikatt","sequence":"additional","affiliation":[{"name":"Department of Tissue Pathology and Diagnostic Oncology, Westmead Hospital , Sydney, NSW 2145 ,","place":["Australia"]},{"name":"Westmead Clinical School, University of Sydney , Sydney, NSW 2145 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena","family":"Shingde","sequence":"additional","affiliation":[{"name":"Department of Tissue Pathology and Diagnostic Oncology, Westmead Hospital , Sydney, NSW 2145 ,","place":["Australia"]},{"name":"Westmead Clinical School, University of Sydney , Sydney, NSW 2145 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A J","family":"Dexter","sequence":"additional","affiliation":[{"name":"Westmead Clinical School, University of Sydney , Sydney, NSW 2145 ,","place":["Australia"]},{"name":"Department of Neurosurgery, Westmead Hospital, Sydney, NSW 2145 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue Lynn","family":"Lau","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Westmead Hospital , Sydney, NSW 2145 ,","place":["Australia"]},{"name":"School of Medicine, Western Sydney University , Sydney, NSW 2560 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2859-5566","authenticated-orcid":false,"given":"Ann","family":"McCormack","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, St Vincent's Hospital , Sydney, NSW 2010 ,","place":["Australia"]},{"name":"Garvan Institute of Medical Research , Sydney, NSW 2010 ,","place":["Australia"]},{"name":"St Vincent's Clinical School, University of New South Wales , Sydney, NSW 2010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"McLean","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Westmead Hospital , Sydney, NSW 2145 ,","place":["Australia"]},{"name":"School of Medicine, Western Sydney University , Sydney, NSW 2560 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"issue":"2","key":"2025070706064811600_lvaf122-B1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1530\/eje.1.02326","article-title":"Pathohistological classification of pituitary tumors: 10 years of experience with the German pituitary tumor registry","volume":"156","author":"Saeger","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025070706064811600_lvaf122-B2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/cncr.20412","article-title":"The prevalence of pituitary adenomas: a systematic review","volume":"101","author":"Ezzat","year":"2004","journal-title":"Cancer"},{"issue":"2","key":"2025070706064811600_lvaf122-B3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1227\/01.NEU.0000223437.51435.6E","article-title":"Pathobiology of pituitary adenomas and carcinomas","volume":"59","author":"Scheithauer","year":"2006","journal-title":"Neurosurgery"},{"issue":"5","key":"2025070706064811600_lvaf122-B4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review","volume":"317","author":"Molitch","year":"2017","journal-title":"JAMA"},{"issue":"12","key":"2025070706064811600_lvaf122-B5","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"2025070706064811600_lvaf122-B6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/modpathol.2015.151","article-title":"Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas","volume":"29","author":"Mete","year":"2016","journal-title":"Mod Pathol"},{"issue":"1","key":"2025070706064811600_lvaf122-B7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.04163.x","article-title":"Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly","volume":"76","author":"Fougner","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2025070706064811600_lvaf122-B8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","article-title":"A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up","volume":"126","author":"Trouillas","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"9","key":"2025070706064811600_lvaf122-B9","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1210\/jc.2017-00773","article-title":"Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification","volume":"102","author":"Raverot","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025070706064811600_lvaf122-B10","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1530\/EJE-22-0812","article-title":"Real-life clinical impact of a five-tiered classification of pituitary tumors","volume":"187","author":"Sahakian","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025070706064811600_lvaf122-B11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/cen.14197","article-title":"A practical algorithm to predict postsurgical recurrence and progression of pituitary neuroendocrine tumours (PitNET)s","volume":"93","author":"Guaraldi","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2025070706064811600_lvaf122-B12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S2213-8587(23)00382-0","article-title":"A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis","volume":"12","author":"Ho","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2025070706064811600_lvaf122-B13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","article-title":"Overview of the 2022 WHO classification of pituitary tumors","volume":"33","author":"Asa","year":"2022","journal-title":"Endocr Pathol"},{"issue":"4","key":"2025070706064811600_lvaf122-B14","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1210\/jc.2010-1048","article-title":"Pituitary incidentaloma: an endocrine society clinical practice guideline","volume":"96","author":"Freda","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025070706064811600_lvaf122-B15","doi-asserted-by":"publisher","first-page":"e230021","DOI":"10.1530\/ERC-23-0021","article-title":"The world health organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal","volume":"30","author":"Villa","year":"2023","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2025070706064811600_lvaf122-B16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1530\/EJE-22-0440","article-title":"Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients","volume":"187","author":"Burman","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025070706064811600_lvaf122-B17","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/cen.13365","article-title":"Younger age is a risk factor for regrowth and recurrence of nonfunctioning pituitary macroadenomas: results from a single Australian centre","volume":"87","author":"Watts","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"2025070706064811600_lvaf122-B18","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1210\/js.2019-00163","article-title":"Residual tumor confers a 10-fold increased risk of regrowth in clinically nonfunctioning pituitary tumors","volume":"3","author":"Maletkovic","year":"2019","journal-title":"J Endocr Soc"},{"issue":"4","key":"2025070706064811600_lvaf122-B19","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1227\/00006123-199310000-00008","article-title":"Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings","volume":"33","author":"Knosp","year":"1993","journal-title":"Neurosurgery"},{"issue":"3","key":"2025070706064811600_lvaf122-B20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1530\/EJE-17-0965","article-title":"Both invasiveness and proliferation criteria predict recurrence of non-functioning pituitary macroadenomas after surgery: a retrospective analysis of a monocentric cohort of 120 patients","volume":"178","author":"Lelotte","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025070706064811600_lvaf122-B21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/ejendo\/lvad079","article-title":"Predictors of pituitary tumour behaviour: an analysis from long-term follow-up in 2 tertiary centres","volume":"189","author":"Lenders","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2025070706064811600_lvaf122-B22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1530\/EJE-18-0749","article-title":"Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre","volume":"180","author":"Asioli","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2025070706064811600_lvaf122-B23","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s11102-023-01319-2","article-title":"Usefulness of a clinicopathological classification in predicting treatment-related outcomes and multimodal therapeutic approaches in pituitary adenoma patients: retrospective analysis on a Portuguese cohort of 129 patients from a tertiary pituitary center","volume":"26","author":"Peixe","year":"2023","journal-title":"Pituitary"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvaf122\/63613528\/lvaf122.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/1\/56\/63613528\/lvaf122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/1\/56\/63613528\/lvaf122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T06:06:52Z","timestamp":1751868412000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/193\/1\/56\/8176841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,6,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf122","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,6,27]]}}}